Agendia Establishes Contract with Humana To Cover MammaPrint - Gilde Healthcare

Agendia Establishes Contract with Humana To Cover MammaPrint

October 19, 2010

IRVINE, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company’s MammaPrint test.  Agendia’s contract with Humana expands the coverage for MammaPrint by more than 17 million lives.  In November 2009, Palmetto GBA, California’s Part B Medicare administrator, established coding guidelines for MammaPrint, allowing healthcare providers from across the United States to submit claims for the test.  MammaPrint is the first and only FDA-cleared breast cancer recurrence test available and has been reimbursed by payors since 2008.

“Humana is dedicated to advancing excellence in healthcare delivery on behalf of its members.  This commitment to quality care and patient safety has now led Humana to include MammaPrint in its medical benefit management program,”

said Bernhard Sixt, Chief Executive Officer of Agendia.

“We are proud that Humana is offering its members coverage for the only gene expression test for breast cancer recurrence which has been cleared by the FDA.”

Humana, headquartered in Louisville, Kentucky, is one of the nation’s largest publicly traded health and supplemental benefits companies, with approximately 10.4 million medical members and approximately 7.2 million specialty-benefit members.  Humana is a full-service benefits-solutions company, offering a wide array of health and supplementary benefit plans for employer groups, government programs and individuals.

About MammaPrint®

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed.  Highly accurate, MammaPrint identifies patients with early metastasis risk — patients who are likely to develop metastases within five years following surgery.  Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk.  In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.  All MammaPrint tests are conducted in Agendia’s CAP-accredited and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company’s tests help physicians more accurately tailor cancer treatments.  Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Irvine, California, and in Amsterdam, the Netherlands.

Media contacts:

Hans Herklots
Agendia
+31.20.462.1557 Office
+31.620.083.509 Mobile
hans.herklots@agendia.com

Todd Aydelotte
Ricochet Public Relations
+1.212.679.3300 x111 Office
todd@ricochetpr.com

Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta...
September 26, 2022

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022